Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC SIYNFEKL TFA | 99.9% | 1013.14 (free acid) | 5 MG
SIYNFEKL TFA is an antigenic peptide, a variant of the major MHC class I-restricted epitope SIINFEKL. It stimulates specific T cells in experimental settings to study competitive interactions between T cells.
- Stimulates specific T cells
- Used to study competitive interaction between T cells
- Exhibits low affinity for OT-I T cell receptor (TCR)
- Applicable for detection of CD8+ T cells
Medchemexpress LLC L-Tyrosine, L-tyrosyl-L-lysyl-L-tyrosyl- (TFA) | 98.1% | 749.73 | 5 MG
YKYY TFA is a blood pressure-lowering peptide isolated from the digest of Undaria pinnatifida. This peptide acts as an angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. It is suitable for use in hypertension research.
- Antihypertensive peptide
- Angiotensin I-converting enzyme (ACE) inhibitor
- Isolated from the peptic digest of wakame Undaria pinnatifida
- For research use only
Medchemexpress LLC Glycyl-Exatecan (TFA) | 1883333-57-0 | 96.9% | 10 MG
Glycyl-Exatecan TFA is a derivative of Exatecan and acts as an anticancer agent. It demonstrates significant antitumor activity.
- Acts as an anticancer agent
- Demonstrates significant antitumor activity
- Suitable for research on cancers such as solid tumors
- Derivative of Exatecan
Medchemexpress LLC Cl2e-SN-38 TFA | 99.5% | 1855.95 | C89H117F3N14O26 | 1 MG
CL2E-SN-38 TFA is an antibody-drug conjugate (ADC) linker-payload provided as the trifluoroacetate (TFA) salt. It incorporates SN-38, the active metabolite of irinotecan, and is intended for research use in ADC development and preclinical studies.
- Highly releasable linker-SN-38 conjugate suitable for ADC research.
- Provided as the trifluoroacetate salt to aid handling and formulation.
- Molecular weight 1855.95 and formula C89H117F3N14O26.
- High purity (reported ~99.5%).
- Available in milligram-scale quantities for assay development and conjugation experiments.
Medchemexpress LLC 4,7,10,13,16-pentaazanonadecanedioic acid ester (TFA) | MFCD34677028 | 98.6% | 1841.72 (free base) | C93H173N5O20S5·xC2HF3O2 | 5 MG
5A2-SC8 TFA is an ionizable amino lipid provided as the trifluoroacetic acid salt for formulation into lipid nanoparticles (LNPs). It is intended for research use to enable efficient delivery of small RNAs, such as siRNA and miRNA, and has documented low in vivo toxicity and COA-verified purity.
- Ionizable amino lipid suitable for LNP formulation.
- Enhances delivery of siRNA and miRNA to target cells.
- Low in vivo toxicity profile reported.
- Provided as the TFA salt to aid formulation and handling.
- COA-verified purity by HPLC (~98.6%).
- Store at -80 °C and protect from light for stability.
Medchemexpress LLC MC-VC-PAB-NH2 TFA | 1616727-21-9 | MFCD00935992 | 99.9% | 772.77 | C33H47F3N8O10 | 5 MG
MC-VC-PAB-NH2 TFA is a cleavable antibody-drug conjugate (ADC) linker used to attach cytotoxic payloads to antibodies and enable intracellular release through enzymatic cleavage. It contains a valine-citrulline dipeptide and a para-aminobenzyl self-immolative spacer and is supplied as the trifluoroacetate salt for stability in research applications.
- Cleavable valine-citrulline linker for cathepsin-mediated payload release.
- Para-aminobenzyl self-immolative spacer to facilitate efficient drug release.
- Supplied as a trifluoroacetate salt for improved stability and handling.
- High purity suitable for research use.
- Soluble in DMSO at high concentration; ultrasonic assistance may be required.
- Store sealed, away from moisture and light; follow recommended low-temperature storage for solutions.
Medchemexpress LLC Cl2e-SN-38 TFA | 99.1% | 1855.95 | C89H117F3N14O26 | 25 MG
CL2E-SN38 TFA is a trifluoroacetate salt of an antibody-linked SN-38 conjugate used for antibody-drug conjugate (ADC) research. It acts as a topoisomerase I inhibitor and is supplied as a high-purity solid characterized for in vitro and in vivo formulation.
- Purity: 99.07% (reported on product page)
- Form: trifluoroacetate salt
- Molecular weight: 1855.95
- Chemical formula: C89H117F3N14O26
- Solubility: soluble in DMSO (example: 100 mg/mL); in vivo formulations reported at ≥2.5 mg/mL
- Storage: protect from light; store under nitrogen; in solvent: -80°C for long term
- Intended use: research reagent for ADC development and topoisomerase I inhibition studies
Medchemexpress LLC Ant308 (TFA) | 99.6% | 3467.10 (free base) | 1 MG
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist that significantly enhances the activation and proliferation of T cells. It inhibits the migration and metastasis and induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling. This compound reduces the expression of MCAM and N-cadherin, making it suitable for studies on acute myeloid leukemia (AML) and uveal melanoma (UVM).
- Vasoactive intestinal polypeptide (VIP receptor) antagonist
- Enhances T cell activation and proliferation
- Inhibits migration and metastasis of melanoma cells
- Induces apoptosis in melanoma tumor cells
- Inhibits VIP-VPAC2 signaling
- Reduces MCAM and N-cadherin expression
- Useful for acute myeloid leukemia (AML) research
- Useful for uveal melanoma (UVM) research
Medchemexpress LLC Cpn-351 TFA | 912.11 (free base) | 1 MG
CPN-351 TFA (compound 9a) is a pentapeptide that acts as a selective antagonist of human NMUR1. Its antagonistic effect on human NMUR1 is 10 times higher than on NMUR2, making it useful in the study of inflammation.
- Selective antagonist of human NMUR1
- Antagonistic effect is 10 times higher on NMUR1 than NMUR2
- Can be used in the study of inflammation
- pA2 of 7.35 for NMUR1
- Kb of 45 nM for NMUR1
Medchemexpress LLC Ribupatide TFA | 2940971-65-1 | 99.8% | 4907.48 | 1 MG
Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. It is orally active and can also be administered by injection, making it suitable for antidiabetic research.
- Dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist
- Can be studied in antidiabetic research
- Orally active
- Can also be administered by injection
Medchemexpress LLC ALX-1393 TFA | 99.8% | 509.45 | 25 MG
ALX-1393 TFA is a selective GlyT2 inhibitor that demonstrates an antinociceptive effect against thermal, mechanical, and chemical stimulations in a rat acute pain model.
- Selective GlyT2 inhibitor
- Exhibits an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model
Medchemexpress LLC Atwlppr peptide tfa | 98.6% | 954.00 | 5 MG
ATWLPPR Peptide TFA is a heptapeptide that acts as a selective neuropilin-1 inhibitor. It prevents VEGF165 binding to NRP-1 and is utilized in angiogenesis research, showing promise in reducing early retinal damage associated with diabetes.
- Inhibits VEGF165 binding to neuropilin-1 by 82% at 100 μM
- Preserves vascular integrity and reduces oxidative stress in vivo
- May decrease early retinal damage associated with diabetes
- Prevents increase of inflammation-associated proteins in the retina